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Ovarian cancer results in more deaths per year than any other cancer of the female reproductive 
system. The low survival rate is partly due to the lack of early detection and the susceptibility to 
relapse. The AKT serine threonine kinase plays a pivotal role in hallmark cellular processes for 
the progression of ovarian cancer, including tumor cell growth and migration. Therapeutic 
targeting of pan-AKT has been problematic, in part due to feedback mechanisms and crosstalk 
with other pathways. The hypothesis for this study is that AKT 1, -2 and -3 isoforms may have 
different roles and regulate cell processes in uniquely varied ways. A transgenic mouse model 
that expresses the SV40 T-antigen viral oncogene and is known to have dramatically increased 
susceptibility to ovarian cancer was utilized, and it had genetic inactivation of either AKT1 or 
AKT2 through targeted deletion of the individual genes because these isoforms have been 
implicated in this cancer.  Primary ovarian tumor cell cultures were established and found to 
exhibit different morphology, proliferation and migration that may indicate a different role for 
the AKT1 and AKT2 isoforms in these contexts. Ovarian tumor cells with absence of AKT1 
predominantly exhibited reduced cell migration when compared to cells with retention of AKT1 
and absence of AKT2. Since AKT is known to be important for epithelial-mesenchymal 
transition (EMT), a process potentially associated with tumor cell metastasis, the expression of 
transcription factors implicated in EMT was assessed by real-time array analysis in ovarian 
tumor cells knocked-out for either AKT1 or AKT2. Twist1, one of the major players in EMT, 
was not detectable in the cells missing the AKT1 isoform. Results indicate an association of 
Twist1 with AKT1 in EMT and migration of ovarian tumors cells. This finding is significant 
because AKT2 has been implicated as the major player of cell migration in human breast cancer 
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cells. Collectively, these findings support a tissue specific role of the AKT isoforms, and may 
provide insights regarding the most useful cell context in order to target components of the AKT 
signaling pathway indirectly affecting EMT in order to prevent tumor progression in patients 





There are not enough words that suffice to express my gratitude to my mentor, principal 
investigator and committee chair Dr. Deborah Altomare. Her invaluable insight, patience and 
immense knowledge about the subject matter have helped me shape up my project with utmost 
novelty and precision. Her recommendation and moral support has helped me lay a strong 
foundation for my future ventures. I would also like to acknowledge the time and support of my 
esteemed committee members Dr. Annette Khaled and Dr. Jihe Zhao. Their guidance was very 
helpful throughout my project.  
I also wish to thank our very dear lab manager Lina Spinel who helped me learn many 
techniques and supported me immensely with her time and skills throughout my project. Special 
thanks to my colleagues, Veethika Pandey and Lisette Dominguez for their contribution. All 
other lab members have always been very supportive and encouraged me to sail through 
smoothly. 
I would like to give a special mention to the various labs at the Lake Nona facility for 
making it a very productive and collaborative research institute. I wish to thank Dr. Subhrangshu 
Guhathakurta and other members from Dr. Yoon Seong Kim’s lab for their support. Insights 
from Shahnawaz Jiwani from Dr. Travis Jewett’s lab, Rebecca Boohaker and other members 
from Dr. Khaled’s lab proved to be very helpful. Thanks to Dr. Masternak’s lab for their support. 
Special thanks to my second family away from home, my friends, Mona Doshi and 




Last but not the least my perennial gratitude to my parents, only second to GOD 
almighty, for giving me the strength and encouragement to achieve my dream and ultimate goal 
of becoming a responsible human being offering my dedication for the betterment of humanity. 
vii 
 
TABLE OF CONTENTS 
 
CHAPTER 1. INTRODUCTION ................................................................................................... 1 
1.1 Ovarian Carcinoma ....................................................................................................... 1 
1.2 PI3K/AKT signaling pathway....................................................................................... 2 
1.3 Isoforms of AKT ........................................................................................................... 3 
1.4 Epithelial Mesenchymal Transition (EMT) .................................................................. 5 
1.5 Molecular regulation of EMT in general ...................................................................... 7 
1.6 EMT in ovarian cancer.................................................................................................. 9 
CHAPTER 2. MATERIALS AND METHODS .......................................................................... 11 
2.1 Cell Culture and Experimental Conditions ................................................................. 11 
2.2 Reagents and Antibodies............................................................................................. 11 
2.3 Cell Migration/ Wound Healing Assay....................................................................... 12 
2.4 Cell Invasion/ Matrigel Assay .................................................................................... 12 
2.5 Induction of Epithelial Mesenchymal Transition ....................................................... 13 
2.6 RNA Isolation ............................................................................................................. 13 
2.7 Real Time PCR/ Array Analysis ................................................................................. 14 
2.8 Protein Extraction ....................................................................................................... 17 
2.9 Western Blot Analysis ................................................................................................ 18 
CHAPTER 3. RESULTS .............................................................................................................. 20 
3.1 Western Blots showing isoform knockouts at protein level ....................................... 20 
3.2 Cell Migration/ Wound Healing Assay....................................................................... 21 
3.3 Cell Invasion/ Matrigel Assay .................................................................................... 23 
viii 
 
3.4 Induction of EMT ....................................................................................................... 25 
3.5 RT
2
 Profiling using EMT array (PAMM-090 SAbiosciences) ................................... 27 
3.6 Validation at Protein levels ......................................................................................... 38 
CHAPTER 4. DISCUSSION ........................................................................................................ 39 




LIST OF FIGURES 
 
Figure 1 Activation of PI3K/Akt signaling pathway. ..................................................................... 2 
Figure 2 General scheme of major molecules in EMT ................................................................... 7 
Figure 3 General schematic showing inhibition of E-cadherin expression and increase in N-
cadherin expression by the transcriptional regulators Twist, Snail and Slug. ................................ 8 
Figure 4 Procedure of Profiling RNA ........................................................................................... 17 
Figure 5 Western blot confirming AKT isoform specific knockout cells .................................... 20 
Figure 6 Cell Migration Assay showing images of the three representative cell types 0174 Akt1 
nulls, 0148 Akt2 nulls, and 01235 control tumor cells taken at regular intervals till 24 hours. ... 21 
Figure 7 DAPI stained nuclei in representative fields of the three cell types ............................... 23 
Figure 8 Quantitative comparison of the invaded cells between three cell types ......................... 24 
Figure 9 Change in morphology from epithelial to mesenchymal at 48 hours and 72 hours using 
TGF β1 and EGF synergy. These images are representative of experiment performed in 
triplicates. ...................................................................................................................................... 25 
Figure 10 Comparison of fold change regulation of Twist1 expression levels in 01235 tumor 
cells with retention of Akt1 and Akt2 (controls), 0174 Akt1nulls and 0148 Akt2 nulls .............. 32 
Figure 11 Comparison of fold change regulation of Snai2 (Slug) expression levels in 01235 
tumor cells with retention of Akt1 and Akt2 (controls), 0174 Akt1nulls and 0148 Akt2 nulls ... 33 
Figure 12 Comparison of fold change regulation of Snai2 (Slug) and Twist1 expression levels in 
01235 tumor cells with retention of Akt1 and Akt2 (controls), 0174 Akt1nulls and 0148 Akt2 
nulls with and without induction of EMT ..................................................................................... 34 
Figure 13 Validation of real time findings using protein band determination. ............................. 38 
Figure 14 A Schematic, indicating the series of events that may explain the observations in the 
cell model.. .................................................................................................................................... 41 
x 
 
LIST OF TABLES 
 
Table 1 Genomic DNA elimination mix preparation ................................................................... 15 
Table 2 Reverse Transcription Mix .............................................................................................. 15 
Table 3 PCR components mix ...................................................................................................... 16 
Table 4 Cell counts before Cell migration Assay ......................................................................... 22 
Table 5 Cell count before Matrigel Assay .................................................................................... 23 
Table 6 Concentration and Purity of Isolated RNA from samples with and without induction of 
EMT for RT
2
 profiling .................................................................................................................. 27 
Table 7 GENE Table listing the genes probed in RT
2
 PCR Array Profiling ................................ 29 
Table 8 P-values of Snai2 and Twist1 calculated from the samples in triplicates of the groups 
with and without EMT induced. ................................................................................................... 35 
Table 9 Fold regulation values determining over or under expression of genes in 0174 Akt1 null 
cells when compared to 01235 controls. ....................................................................................... 35 
Table 10 Fold regulation values determining over or under expression of genes in 0148 Akt2 null 
cells when compared to 01235 controls. ....................................................................................... 36 
Table 11 Fold regulation values determining over or under expression of genes in 0174 Akt1 null 




CHAPTER 1. INTRODUCTION 
 
1.1 Ovarian Carcinoma 
 
Ovarian cancer is the fifth most common type of cancer causing fatalities in women. This 
second-most deadly gynecological disorder was diagnosed in 21,880 women in United States, 
causing 13,850 estimated deaths in the year 2010 (Jemal, Siegel et al. 2010). Treatment options 
include surgery and administration of carboplatin and paclitaxel as combination chemotherapy. 
Intensive chemotherapy has improved the 5- year survival rate by 8% in the past 30 years. 
However most patients are presented at an advanced FIGO stage III-IV which increases the 
mortality rate along with acquired resistance to chemotherapy (Agarwal and Kaye 2003) 
(Cannistra 2004) (Hennessy, Coleman et al. 2009) (Davidson, Trope et al. 2012). This shows the 
aggressive nature of ovarian carcinoma. Only 20% of the patients diagnosed with ovarian cancer 
are in their first stage and can be completely cured by intensive treatments. Ninety percent of the 
ovarian malignancies are initiated by the cancer cells arising from the epithelial cells of the 
surface of ovary (Shan and Liu 2009).  The outer surface of the ovary is surrounded by a single 
layer of peritoneal mesothelium, which is termed as ovarian epithelium. It is said to be a 
derivative of celomic epithelial cells, which is responsible for generation of female reproductive 
organs (Connolly, Bao et al. 2003). It is thought that the pluripotent potential of ovarian cancer 
cells to differentiate into various cancer cell types is due to their celomic epithelial cell origin 
(Connolly, Bao et al. 2003). According to the differentiation of the tumor cells, ovarian cancer is 
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divided into four major types- serous, endometriod, mucinous and clear cell. Serous is the most 
common type of ovarian cancer and is further categorized into low grade and high grade serous 
tumors (Landen, Birrer et al. 2008) (Cho and Shih Ie 2009). It is postulated that mutations in 
KRAS/BRAF genes, (Singer, Oldt et al. 2003) unbalanced regulation of p53 & BRCA1/2 and 
Wnt/β-catenin/TCF pathways, mutation in the PTEN tumor suppressor and activation of 
phosphoinositide 3-kinase (PI3 kinase)/AKT pathway, form the genetic basis of epithelial 
ovarian cancer (Yap, Garrett et al. 2008). The main focus of my project is the AKT pathway and 
the role of the two isoforms of AKT (AKT1 and AKT2) in epithelial ovarian cancer cells. 
 
1.2 PI3K/AKT signaling pathway 
 
 
Figure 1 Activation of PI3K/Akt signaling pathway. 
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The serine/threonine kinase AKT/protein kinase B, which serves as a downstream target 
of PI3 kinase, has key roles in the regulation of cell growth and proliferation, survival, motility 
and metabolism (Bellacosa, Testa et al. 1991). G protein coupled receptors and tyrosine kinases 
activate PI3 kinase by phosphorylation. This in turn generates phosphoinositides. AKT 
translocates from the cytosol to the plasma membrane where the pleckstrin homology (PH) 
domain binds phosphatidylinositol (3, 4, 5)-trisphosphate (PIP3). AKT is phosphorylated in the 
C-terminal regulatory domain (RD) on Thr308 by PDK1 and Ser473 by mTORC2 (Vivanco and 
Sawyers 2002). This activated AKT performs a plethora of necessary cellular functions such as 
prevention of apoptosis by enhancing glucose utilization, increasing the levels of Bcl-2 or Bcl-xl; 
(Maestro, Dei Tos et al. 1999) enhancing nuclear localization of MDM2, (Mayo and Donner 
2001) activation of NF-κB pathway, inhibition of cytochrome C release from mitochondria, 
inactivation of Bad and Bax (Testa and Bellacosa 2001). Akt contributes to cancer progression 
by inhibiting p21, p27, GSK3β and activating mTOR (Nicholson and Anderson 2002).  
 
1.3 Isoforms of AKT 
 
AKT is found as three isoforms AKT-1, -2, and -3. All three exhibit high sequence 
homology. The genes reside on different human chromosomes. Due to less sequence homology 
between the C- and N- terminal domains of the three isoforms it is believed that they have 
different physiological and biological functions in normal as well as cancer cells (Cheng, 
Ruggeri et al. 1996). It has been observed that AKT1 is uniformly expressed in various organs. 
Over expression of wild type AKT2 has been shown to transform the NIH 3T3 cells (Bellacosa, 
4 
 
de Feo et al. 1995). Overexpression of AKT2 is seen in 15% of ovarian cancer and 20% of 
pancreatic cancer (Carpten, Faber et al. 2007). Recently it has been studied that mutation in the 
PH domain of AKT1 promotes its localization to the plasma membrane and it has been studied to 
transform cells in vitro and induce leukemia in mice (Altomare and Testa 2005).  Over activation 
of AKT kinase due to mutation in itself or upstream signaling molecules is found in 50% of 
human tumors making it a highly attractive target for anti-cancer therapy (Irie, Pearline et al. 
2005). Recently there has been speculation for opposing roles for the AKT1 and AKT2 isoforms 
in cell motility and invasion. In human breast cancer cell lines AKT1 has shown to be an 
inhibitor of cell motility. Knockdown studies showed that a decrease in the levels of AKT1 
increased cell motility whereas a decrease in AKT2 did not show substantial effect. Down-
regulation of AKT1 caused an increase in ERK, which was supposed to give anti-migratory 
property to AKT1 (Yoeli-Lerner, Yiu et al. 2005). A conflicting study carried out in breast 
cancer cell lines published that an anti-migratory effect of AKT1 was independent of the ERK 
pathway. AKT1 mediated activation of MDM2 ubiquitin ligase resulted in proteosomal 
degradation of NFAT- nuclear factor of activated T cells, which is a pro-migratory transcription 
factor (Liu, Radisky et al. 2006). Another study in mammary epithelial breast cancer cells 
expressing myristoylated (myr) AKT1 corroborated the anti-migratory role of AKT1, but 
proposed a completely different mechanism. Phosphorylation of targeted tumor suppressor 
tuberous sclerosis complex 2 (TSC2) and its degradation was found in cells over expressing myr-
AKT1. This led to a reduction in Rho-GTPase levels and a decrease in focal adhesions and actin 
stress fibers to reduce cell motility and invasion (Liu, Radisky et al. 2006). A recent publication 
linked Twist, a transcription factor implicated in epithelial mesenchymal transition with AKT2 to 
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cause its up-regulation and induce cell motility and invasion (Cheng, Chan et al. 2007) . All 
these studies, which were carried out in breast cancer cell lines, established the conflicting roles 
of AKT1 and AKT2 in cell migration and invasion. Recent studies in non-small cell lung cancer 
showed that AKT1 is predominant regulator of cell proliferation and migration whereas AKT2 is 
largely inconsequential (Lee, Kim et al. 2011). Thus the different roles of AKT1 and AKT2 
become a matter of cell context and it could be possible to find totally reversed roles of the two 
isoforms in a different organ/cell type. In our lab we are equipped with a transgenic mouse 
model that expresses the SV40 T antigen viral oncogenes in ovarian cells; the mice were 
genetically inactivated either for AKT1 or AKT2 and are predisposed to forming ovarian tumors 
and derived at least two different cell lines with targeted deletion of the individual genes. This 
unique model has helped me to delineate the distinct roles of AKT1 and AKT2 in ovarian cancer 
cells. The transcription factors that regulate both the isoforms can be highlighted and their role in 
epithelial mesenchymal transition can be defined.  
 
1.4 Epithelial Mesenchymal Transition (EMT) 
 
A very complex and interesting phenomenon in which, epithelial cells that line the organs 
and tissues, are transitioned into becoming spindle shaped mesenchymal cells and gain motility, 
is called Epithelial Mesenchymal Transition (EMT) (Yang and Weinberg 2008). EMT is 
desirable and quite important during embryogenesis, tissue fibrosis and wound healing, it occurs 
in a controlled fashion and is brought about by various events of molecular transformations in a 
cell which triggers the phenotypic switch in the cell to become stem like from the current 
6 
 
epithelial phenotype (Yang and Weinberg 2008). As mentioned earlier there is a constant inter-
conversion between the two phenotypes, epithelial and mesenchymal during embryogenesis. 
This inter-conversion is necessary for the formation of different germ layers and helps the 
differentiated cells reach their destination. Once the cells gain motility and reach their destination 
there is an event of reverse EMT called MET mesenchymal to epithelial transition, which helps 
them revert to an epithelial phenotype. Similar pattern has been observed in highly metastatic 
cancer. (Thompson, Newgreen et al. 2005). 
In order to understand the logic behind this conversion of cells from one phenotype to 
other it is important to learn the distinct features of the two phenotypes. Epithelial cells possess 
adherent interactions, which are cohesive in nature and form epithelial sheets of the cells that line 
the organ or tissue. These sheets are held together by tight junctions and desmosomes, which are 
in turn supported by surfactant molecules like E-cadherin, ZO-1, keratins and collagen. The 
epithelial cells demonstrate a very nice tissue framework, the cells are rested on a basal surface 
at one end and the upper layer is free. The epithelial cells are thus termed to be bipolar in nature. 
(Thompson, Newgreen et al. 2005). 
Mesenchymal cells lack the cellular framework as seen in the epithelial cells. They have 
reduced adhesive property but can still stay together while moving towards their destination. 
They do not have a basement membrane as in the case of epithelial tissue network. The major 
molecules that impart mesenchymal properties to these cells are N-cadherin, fibronectin, 
Vimentin and some others. Various transcription factors are implicated in this process of 
transition from epithelial to mesenchymal phenotype.(Thompson, Newgreen et al. 2005).  
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Summarizing the basics of EMT, it is clear that in this phenomenon the cells lose their 
epithelial characteristics like strong tissue framework and become more flexible and motile in 
phenotype which is very close to being a stem cell. There is a plethora of molecular events that 
facilitate this process and its reverse as well. Intensive research is being done in this area 
especially after the implication of EMT in cancer metastasis. (Thiery, Acloque et al. 2009). 
 
1.5 Molecular regulation of EMT in general 
 
Figure 2 General scheme of major molecules in EMT 
 
Various growth factors play a vital role in inducing EMT during embryogenesis as well 
as cancer progression. Among the wide variety of growth factors the main players are 
transforming growth factor beta 1 (TGF β1), epidermal growth factor (EGF), fibroblast growth 
factor (FGF), platelet-derived growth factor (PDGF), insulin like growth factor (IGF), vascular 
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endothelial growth factor (VEGF), Prostaglandin E2, stem cell growth factor, parathyroid 
hormone, bone morphogenetic proteins (BMP) and hepatocyte growth factor (HGF) (Kalluri and 
Weinberg 2009). Along with the morphological changes there are a number of events causing 
either up regulation or down regulation of various molecules, which can, in general, be identified 
as molecular markers of EMT. The markers that are generally down regulated include E-
cadherin, Claudins, ZO-1, cytokeratins, occludin, MUC1, laminin- 1, entactin and microRNA 
200 family. The over expressed markers comprise of molecules namely, transcription factors like 
Twist, Snail, Slug, Zeb1, SIP1, KLF8, Goosecoid, FoxC2 as well as Vimentin, fibronectin and 
miR10b. (Zeisberg and Neilson 2009) (Thiery, Acloque et al. 2009) (Davidson, Trope et al. 
2012). Most of the molecules mentioned above are altered during the process of embryonic 
development as well as metastasis. The only difference between the two processes is that in the 
later, the cells lose their target recognition specificity and there is activation of autocrine loops as 
well as enhanced angiogenesis, all of which support aggressive tumor growth and metastasis  
(Ahmed, Thompson et al. 2007).   
 
Figure 3 General schematic showing inhibition of E-cadherin expression and increase in N-
cadherin expression by the transcriptional regulators Twist, Snail and Slug. 
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1.6 EMT in ovarian cancer 
 
This complex phenomenon is being studied in depth and with every significant 
observation it is being repeatedly proved that EMT in ovary is an exception to the norm 
(Sundfeldt, Ivarsson et al. 2001). One of the most common markers of EMT in majority of the 
tissues undergoing metastasis is decrease in E-Cadherin expression and increase in its N-
Cadherin counterpart. Although increased levels of soluble E-Cadherin have been reported in 
cyst fluids of malignant ovarian tumors (Davidson 2001), there are reports of either the E-
Cadherin expression levels being increased or them remaining the same as in normal ovarian 
tissue  (Christiansen and Rajasekaran 2006). This non-canonical observation was also 
rationalized by stating that the up regulation of E-cadherin indicated the survival signals for the 
cancer cell or transition to mesenchymal to epithelial phenotype after EMT (Patel, Madan et al. 
2003). Ovarian tumor masses that progress to advanced tumor stages have also been reported to 
have enhanced expression P-Cadherin (Alipio, Jones et al. 2011).  
The cadherin levels are highly regulated by hallmark players of EMT reported as Snail, 
Slug, Zeb family, Twist family and several other factors. The regulation of these players is 
poorly understood in vitro as well as at the clinical tier. It can be stated with the present literature 
that expression profiles of EMT related molecules are significantly different in ovarian cancer 
cells when compared to other types of cancer. This includes higher levels of E-Cadherin and 




These nuances make ovarian carcinoma progression unique in its own way and raise a lot 
of unanswered questions. Although the studies are not able to completely define EMT in ovarian 
cancer, there is compelling evidence which links EMT to various signaling mechanisms present 
in the cell. The cross talk between the signaling pathways in the presence and absence of EMT, 
and also sometimes contributing to EMT, is very interesting and an in-depth study of this area 
could uncover certain hidden facts, which might prove to be important therapeutic targets in the 
treatment of ovarian carcinoma. 
In this project there have been developments which link Akt isoform specificity to some 




CHAPTER 2. MATERIALS AND METHODS 
 
2.1 Cell Culture and Experimental Conditions 
 
Ovarian surface epithelial tumor cells were cultured in Dulbecco’s Modification of 
Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum, L-glutamine and 
penicillin-streptomycin. Experiments were performed with cells in passage 12-20. Confluent 
cells were dissociated using 0.05% Trypsin. The cells were maintained in 37°C, 5 % CO2 
incubator under sterile conditions. 
2.2 Reagents and Antibodies 
 
Murine TGF β1 (#5231LF; lot 3) was purchased from Cell Signaling Technology, Inc. 
Antibodies against Akt1 (#2938S; lot 2), Akt2 (#3063; lot 4), total Akt (#9272; lot 17), β-actin 
(#MAB1501; lot NG1848416), N-cadherin (#2019-1; lot YE011803R) and E-cadherin (#3195; 
lot 10) were also purchased from Cell Signaling Technology, Inc. Murine Epidermal growth 





2.3 Cell Migration/ Wound Healing Assay 
 
A 24-well plate format cell migration assay kit (Cell Biolabs, Inc.) was used.   In brief, 
the wells had a gel spot in the center, which was biocompatible but did not allow cells to adhere 
to it. The wells to be used were pretreated by adding 500 µl of gel pretreatment solution (Cell 
Biolabs, Inc.) and incubating the plate at room temperature for 20 minutes. The wells were then 
treated with gel wash solution and incubated at room temperature for 60 minutes. AKT1 nulls, 
AKT2 nulls and control tumor cells were seeded in three different pretreated wells at the density 
of 5 x 10
5 
cells per well in 500 µl of media. The cells were allowed to attach for 5 hours. The 
wells were treated with the gel removal agent for 30 minutes at 37°C. Gel removal agent was 
prepared by diluting 100 X gel removal agent (Cell Biolabs, Inc.) to 1X in media. The wells were 
repeatedly washed three times with media and 1 ml of fresh media was administered. The wells 
were photographed every 2 hours starting at 0 hour being the time the gel spot was removed 
using the gel removal agent. 
 
2.4 Cell Invasion/ Matrigel Assay 
 
BD BioCoat Matrigel Invasion chambers were used to gauge invasive potential of the 
cells. 500 µl warm media was added to the determined inserts and the companion wells to 
rehydrate them. The media was carefully removed after 2 hours and fresh media was added to 
the companion wells. The cells were prepared by suspending them in DMEM. The cells were 





per ml. The cells were added on the top layer of the membrane in the inserts. The invasion 
chambers were incubated at 37°C, 5% CO2 for 22 hours. The non-invaded cells were swabbed 
off the upper surface of the Matrigel-coated membrane using sterile cotton swabs by applying 
gentle but firm pressure. The scrubbing was repeated using swabs moistened in media. The 
invaded cells were fixed using 4% paraformaldehyde for 10 minutes. The fixed cells were 
stained using a nuclei staining dye, 4', 6-diamidino-2-phenylindole (DAPI) for 2 minutes. The 
inserts with the fixed stained cells were mounted on a slide with a drop of oil. 
 
2.5 Induction of Epithelial Mesenchymal Transition 
 
Cells were seeded in 6-well plates at the density of 10
5
 per ml and nourished with culture 
media containing 10% FBS. After 24 hours media with 5% FBS was introduced in the cells 
along with 2 µl of 100 µg/ml TGF β1 and 10 µl of 100 ng/ml of EGF. The effect on the 
morphology of the cells was observed microscopically every 24 hours.  
2.6 RNA Isolation 
 
RNA was isolated using TRIzol reagent (Ambion). 1 ml of TRIzol reagent was added to 
each well in the 6 well plates. The cells were scrapped off using a cell scrapper and collected in 
sterile 1.5 ml tubes. The tubes were incubated for 5 minutes at room temperature for complete 
homogenization and dissociation of the nucleoprotein complex. 200 µl of chloroform was added 
to the tubes. The tubes were capped securely and vortexed for 15 seconds. They were allowed to 
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incubate at room temperature for 3 minutes. The samples were centrifuged at 12,000 x g for 15 
minutes at 4°C. The aqueous phase was removed carefully and transferred into a new tube. 500 
µl of 100% isoproponal was added to the aqueous phase. The tubes were incubated at room 
temperature for 10 minutes. They were centrifuged at 12,000 x g for 10 minutes at 4°C. The 
supernatant was then removed and 1 ml of 75% ethanol was added to the RNA pellet. The 
sample was vortexed briefly and centrifuged at 7,500 x g for 5 minutes at 4°C. The RNA was air 
dried for 10 minutes and resuspended in 50 µl of RNase free water. RNA solution was incubated 
at 65°C for 5 minutes and then cooled on ice for 2 minutes. 




 Profiler PCR Arrays are provided in 96-well plate format. (SAbiosciences, Qiagen). 
These plates contain 84 primer assays for EMT and 5 housekeeping genes. In addition, one well 
contains genomic DNA control, 3 wells contain reverse transcription controls and 3 wells contain 
positive PCR control.  
Fresh RNA was isolated as mentioned in the section 2.6 of Material and Methods. After 
extraction, the RNA, it was dissolved in 50 µl of RNase free water. The tubes containing RNA 
were briefly left open and heated at 65°C for 5 minutes in a water bath. The tubes were then 
cooled on ice for 2 minutes. The RNA concentration was determined using a Nanodrop machine 
(Thermo Scientific). Concentration and purity of RNA were calculated.  
In order to prepare cDNA using the RT
2
 First Strand Kit provided by Qiagen, RNA 




Table 1 Genomic DNA elimination mix preparation 
Component Amount per reaction 
RNA  Scaled to 2 µg total RNA 
Buffer GE DNA elimination mix 2 µl 
RNase free water Volume adjusted to 10 µl 
Total Volume  10 µl 
 
The reagents of the RT
2
 First Strand Kit were thawed and briefly centrifuged to bring the 
contents to the bottom of the tubes. The genomic DNA elimination mix was prepared according 
to Table 1. The mix was incubated for 5 minutes at 42°C, and then placed immediately on ice for 
at least 1 minute.    
Table 2 Reverse Transcription Mix 
Component Volume per reaction 
5x Buffer BC3 4 µl 
Control P2 1 µl 
RE2 reverse transcriptase mix  2 µl 
RNase free water 3 µl 
Total Volume 10 µl 
 
The reverse-transcription mix was prepared according to Table 2. 10 µl of reverse-
transcription mix was added to each tube containing 10 µl of genomic DNA elimination mix. It 
was mixed gently by pipetting up and down. 
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This 20 µl mix was incubated at 42°C for exactly 15 minutes. The reaction was 
immediately stopped by incubating it in 95°C for 5 minutes. These cycles were carried out in a 
thermo cycler (Eppendorf Mastercycler).  
After the incubation period was over, 91 µl of RNase free water was added to each cDNA 
synthesis reaction. The contents were mixed gently by pipetting up and down. The reactions 
were stored in -20°C until they were used for real time experiments. Generally the process of 
extracting RNA to real time profiling was completed within 48 hours for each sample.  
For setting up the real time PCR profiling 96-well plate RT
2
 SYBR Green Mastermix was 
used provided by Qiagen. The tube was briefly centrifuged to bring the contents to the bottom.  
Table 3 PCR components mix 
Array format 96- well plate 
2x RT
2
 SYBR Green Mastermix 1350 µl 
cDNA synthesis reaction 102 µl 
RNase free water 1248 µl 
Total Volume 2700 µl 
 
The PCR component mix was prepared in a loading reservoir according to Table 3. 25 µl 
of this reaction mix was dispensed in each well of the 96-well EMT-PCR plate array. The array 
was tightly sealed with optical adhesive film. It was centrifuged for 1 minute at 1000 x g at room 
temperature.  
The Applied Biosystems 7500 fast real-time thermo cycler was used and was 
programmed for 1 cycle for 10 minutes at 95°C followed by 40 cycles each for 15 seconds at 
95°C and 1 minute at 60°C. After the run, Ct values were obtained and presented as raw data, 
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which could be further processed using the PCR data analysis software provided by 
SAbiosciences.   
 
 
Figure 4 Procedure of Profiling RNA 
 
2.8 Protein Extraction 
 
The media was aspirated from the well containing cells from which protein were to be 
extracted. Ice-cold PBS was added to the wells. The cells were scrapped off and then suspended 
in PBS gently using a pipette. The cell suspension was centrifuged in 4°C at 1,100 rpm for 5 
minutes. The PBS was pipetted off and depending upon the size of the cell pellet obtained 100-
200 µl of ice-cold cell lysis buffer was added to the tubes. The cells were suspended using a 
pipette. 1 µl of PMSF and 2 ul of proteinase inhibitor cocktail were also added. The tubes were 
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incubated at -80°C for 30 minutes. The contents were thawed at room temperature. The contents 
were centrifuged at 15,000 rpm for 1 min in 4°C. The supernatant was carefully transferred to a 
new tube which was kept on ice. The supernatant contained the protein and was always kept on 
ice.  
 
2.9 Western Blot Analysis 
 
12% any-KD SDS-polyacrylamide gels (Bio-Rad) were used for electrophoresis of 60 µg 
protein samples. Protein samples were combined with Laemmli’s SDS-sample buffer (final 1X) 
in boiling water for five minutes. Simultaneously, running buffer (10X Tris-SDS-Glycine 
Running Buffer, pH 8.3, 30.3 g Tris base, 144.0 g glycine and 10 g SDS) was kept in the -20°C 
freezer to allow chilling before running electrophoresis. The samples were allowed to cool and 
were loaded left to right starting with molecular marker. Electrophoresis was run for 15 minutes 
at 20mA and for 1 hour at 40mA. The gel after electrophoresis was prepared for transfer of 
protein to a nitrocellulose membrane (GE Healthcare Amersham Hybond ECL Nitrocellulose 
Membrane). Transfer was done at 25V at 4˚C for 2 hours (Invitrogen). Post-transfer the 
membranes were blocked in blocking agent (5% milk + TBS-Tween (10 ml)), shaking at 4˚C 
overnight or at room temperature for 2 hours. After blocking, the membranes were rinsed twice 
in TBS-T and then washed 3 times for 5 minutes.  
The primary antibody was diluted to optimal concentration in wash buffer or blocking 
solution (TBS-Tween + milk). The blocked membrane was incubated with diluted primary 
antibody for 2 hours at room temperature with rocking. The membrane was covered with plastic 
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to avoid evaporation. The membrane was rinsed two times in TBS, and then washed 3 times for 
5 minutes in TBS-Tween (0.1%) rocking at room temperature. The secondary antibodies were 
diluted to optimal concentration in TBS-Tween + milk. The membrane was rinsed three times in 
wash buffer (TBS-Tween + milk), followed by 4 times for 5 minutes in wash buffer, shaking at 
room temperature.  
Using advanced chemiluminescent agent (SuperSignal West Dura Stable Peroxide Buffer 
1 ml + SuperSignal West Dura Luminol/ Enhancer Solution 1 ml – Thermo Scientific). The 
membranes were first exposed to this solution, dried and then exposed to an X-ray film (Classic 
Blue Autoradiography Film BX). The film was developed (AFP image film processor) and thus 
protein bands were identified.  
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CHAPTER 3. RESULTS 
3.1 Western Blots showing isoform knockouts at protein level 
 
All the available cell types extracted from the transgenic mice were validated at protein 
levels and it was established that the following cell types were successfully extracted and 
established under the preferred cell culture conditions: 
1. Tumor cells derived from mouse 0174 with Akt1 knockout. 
2. Tumor cells derived from mouse 0148 with Akt2 knockout. 
3. Tumor cells derived from mouse 0192 with Akt2 knockout. 
4. Tumor cells derived from mouse 0109 with retention of Akt1 and Akt2 
5. Tumor cells derived from mouse 07D with retention of Akt1 and Akt2. 
6. Tumor cells derived from mouse 01235 with retention of Akt1 and Akt2. 
 
 




3.2 Cell Migration/ Wound Healing Assay 
Hours 0174 Akt1 knockouts 0148 Akt2 knockouts 01235 controls 
0  
   
 
6  
   
 
12  
   
 
24  
   
 
Figure 6 Cell Migration Assay showing images of the three representative cell types 0174 




The experiment was repeated three times. The images of the cells seeded in the cell 
migration assay 24 well plates, taken at regular time intervals clearly suggest a significant 
difference among the three cell lines in the time each takes to migrate and occupy the void space. 
The three cell types were obtained from ongoing cell culture conditions. After processing 
the cells for counting, the following counts were obtained. (Images were taken using Zeiss Axio 
Observer.A1 microscope, AxioCamCc3 camera, EC PCanNeofluar 10x/0.30 Ph1 objective) 
Table 4 Cell counts before Cell migration Assay 
0174 Akt1 nulls 2.7 x 10
6
 cells per ml of media 
0148 Akt2 nulls 2.7 x 10
6
 cells per ml of media 
01235 control tumor cells 2.8 x 10
6
 cells per ml of media 
 
The cells were diluted in media to a uniform concentration of 5 x 10
5
 cells per 500 µl of 
media. 
After seeding 5 x 10
5
 cells in each well, the void circular space in the center of the well 
protected by gel was released of the gel in 4 hours. Upon release of the gel block the cells 
attached were arranged as shown in the Figure 8 in the 0 hours panel. The experiment was 
conducted within 28 hours of seeding of cells. This time frame reduced the possibility of cells 
dividing and occupying the space rather than migration, as the doubling time of the employed 
cell types was characterized by CFSE cell proliferation staining (Invitrogen) as being more than 
24 hours. It was observed that 0148 Akt2 nulls (with retention of Akt1) migrated at a faster rate 
than 0174 Akt1 nulls. 01235 cells with retention of Akt1 and Akt2 isoforms were not 
significantly different from 0148 cells in their migration rate. This suggests that Akt1 is 
important for the cell migration. Loss of Akt1 reduces the cell migration rate to a noteworthy 
extent.    
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3.3 Cell Invasion/ Matrigel Assay 
Table 5 Cell count before Matrigel Assay 
0174 Akt1 nulls 5.6 x 10
6
 cells per ml of media 
0148 Akt2 nulls 4.4 x 10
6
 cells per ml of media 
01235 control tumor cells 3.8 x 10
6
 cells per ml of media 
 
All the three types of cells were prepared in dilutions such that they contained 5 x 10
4
 
cells per ml of DMEM. 500 µl of this cell suspension was added to the upper surface of the 
membrane and the experiment was performed as mentioned in section 2.4. The DAPI stained 
lower membrane was observed under the microscope and counts from 10 random fields per cell 
type were taken. An average of these counts was taken and compared for quantitative analysis of 
cell invasion.  
 




The representative fields of the DAPI stained nuclei indicate that in the cells that do not 
have Akt1, 0174 Akt1 null cells, have the least number of cells invaded to the lower side of the 
membrane when compared to the cells that retain Akt1 isoform. 0148 Akt2 null cells show more 
cells invaded than 01235 control cells.  
 
Figure 8 Quantitative comparison of the invaded cells between three cell types 
 
Figure 6 shows the plot of average number of cells per field in each cell type. In 0148 
Akt2 null cells, average count was 107 cells, 01235 controls showed an average count of 72 cells 
whereas 0174 Akt1 null cells had an average of 40 cells that invaded to the lower side of the 





3.4 Induction of EMT 
 
A combination of TGF β1 and EGF was used to induce EMT characteristics in the cells 
(Xu, Lao et al. 2012). At concentrations of 100 ng/ml of TGF β1 and 1 ng/ml of EGF, it was 
observed that combination treatment with the two growth factors induced EMT in the cells 48 
hours after treatment.  








   
01235 
ctrl. 
   
Figure 9 Change in morphology from epithelial to mesenchymal at 48 hours and 72 hours using 





There is a difference in morphology from epithelial shape (as seen in 48 hours untreated 
column for all the three types) to mesenchymal spindle shaped cells (as seen in the 48 hours and 
72 hours treatment columns). 
Induction of EMT using 100 ng/ml TGF β1 alone was also seen after 96 hours. This 
indicates that the positive influence between two growth factors TGF β1 and EGF accelerated the 







 Profiling using EMT array (PAMM-090 SAbiosciences) 
Using EMT array analysis it was possible to test if there were any differences in the 
association of transcription factors and other players of EMT, with the two different Akt 
isoforms. The EMT array comprised of 84 genes implicated in the overall process of EMT. 
Three sets of experiments were prepared of cells with and without induction of EMT using TGF 
β1 and EGF. RNA was collected from all the cells in the purest quality possible as defined by the 
A260:A280 and A260:A230    values.  
 





Sample Conc. (µg/µl) A260:A280 A260:A230 
Set 1 
0174 Akt1 null not induced 1.110 2.02 1.80 
0148 Akt2 null not induced 0.805 1.97 1.36 
01235 controls not induced 1.187 2.03 1.81 
0174 Akt1 null EMT induced 0.851 2.03 1.64 
0148 Akt2 null EMT induced 0.773 2.04 1.61 
01235 control EMT induced 0.781 2.04 1.74 
Set 2 
0174 Akt1 null not induced 1.287 1.93 1.90 
0148 Akt2 null not induced 1.26 1.87 2.12 
01235 controls not induced 1.712 1.93 2.15 
0174 Akt1 null EMT induced 0.3408 1.87 1.88 
0148 Akt2 null EMT induced 1.424 1.93 2.13 
01235 control EMT induced 1.712 1.93 2.15 
Set 3 
0174 Akt1 null not induced 0.6979 1.96 2.05 
0148 Akt2 null not induced 0.4785 1.91 2.12 
01235 wild type not induced 0.519 1.90 2.10 
0174 Akt1 null EMT induced 1.774 2.0 2.21 
0148 Akt2 null EMT induced 0.8737 1.95 2.22 




After determining RNA concentration and purity, it was used for RT
2
 profiling of EMT 
array. Table 7 shows the list of the genes that can be tested using this array. 
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Table 7 GENE Table listing the genes probed in RT
2
 PCR Array Profiling 
Position Symbol Description 
A01 Ahnak AHNAK nucleoprotein (desmoyokin) 
A02 Akt1 Thymoma viral proto-oncogene 1 
A03 Bmp1 Bone morphogenetic protein 1 
A04 Bmp7 Bone morphogenetic protein 7 
A05 Cald1 Caldesmon 1 
A06 Camk2n1 Calcium/calmodulin-dependent protein kinase II inhibitor 1 
A07 Cav2 Caveolin 2 
A08 Cdh1 Cadherin 1 
A09 Cdh2 Cadherin 2 
A10 Col1a2 Collagen, type I, alpha 2 
A11 Col3a1 Collagen, type III, alpha 1 
A12 Col5a2 Collagen, type V, alpha 2 
B01 Ctnnb1 Catenin (cadherin associated protein), beta 1 
B02 Dsc2 Desmocollin 2 
B03 Dsp Desmoplakin 
B04 Egfr Epidermal growth factor receptor 
B05 Erbb3 
V-erb-b2 erythroblastic leukemia viral oncogene homolog 3 
(avian) 
B06 Esr1 Estrogen receptor 1 (alpha) 
B07 F11r F11 receptor 
B08 Fgfbp1 Fibroblast growth factor binding protein 1 
B09 Fn1 Fibronectin 1 
B10 Foxc2 Forkhead box C2 
B11 Fzd7 Frizzled homolog 7 (Drosophila) 
B12 Gng11 Guanine nucleotide binding protein (G protein), gamma 11 
C01 Gsc Goosecoid homeobox 
C02 Gsk3b Glycogen synthase kinase 3 beta 
C03 Igfbp4 Insulin-like growth factor binding protein 4 
C04 Il1rn Interleukin 1 receptor antagonist 
C05 Ilk Integrin linked kinase 
C06 Itga5 Integrin alpha 5 (fibronectin receptor alpha) 
C07 Itgav Integrin alpha V 
C08 Itgb1 Integrin beta 1 (fibronectin receptor beta) 
C09 Jag1 Jagged 1 
C10 Krt14 Keratin 14 
C11 Krt19 Keratin 19 
C12 Krt7 Keratin 7 
D01 Mitf Microphthalmia-associated transcription factor 
D02 Mmp2 Matrix metallopeptidase 2 
D03 Mmp3 Matrix metallopeptidase 3 
D04 Mmp9 Matrix metallopeptidase 9 
D05 Msn Moesin 
D06 Mst1r Macrophage stimulating 1 receptor  
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Position Symbol Description 
D07 Mtap1b Microtubule-associated protein 1B 
D08 Nodal Nodal 
D09 Notch1 Notch gene homolog 1 (Drosophila) 
D10 Nudt13 Nudix (nucleoside diphosphate linked moiety X)-type motif 13 
D11 Ocln Occludin 
D12 Pdgfrb Platelet derived growth factor receptor, beta polypeptide 
E01 Plek2 Pleckstrin 2 
E02 Pppde2 PPPDE peptidase domain containing 2 
E03 Ptk2 PTK2 protein tyrosine kinase 2 
E04 Ptp4a1 Protein tyrosine phosphatase 4a1 
E05 Rac1 RAS-related C3 botulinum substrate 1 
E06 Rgs2 Regulator of G-protein signaling 2 
E07 Serpine1 Serine (or cysteine) peptidase inhibitor, clade E, member 1 
E08 Sip1 Survival of motor neuron protein interacting protein 1 
E09 Smad2 MAD homolog 2 (Drosophila) 
E10 Snai1 Snail homolog 1 (Drosophila) 
E11 Snai2 Snail homolog 2 (Drosophila) 
E12 Snai3 Snail homolog 3 (Drosophila) 
F01 Sox10 SRY-box containing gene 10 
F02 Sparc Secreted acidic cysteine rich glycoprotein 
F03 Spp1 Secreted phosphoprotein 1 
F04 Stat3 Signal transducer and activator of transcription 3 
F05 Steap1 Six transmembrane epithelial antigen of the prostate 1 
F06 Tcf7l1 Transcription factor 7-like 1 (T-cell specific, HMG box) 
F07 Tcf4 Transcription factor 4 
F08 Tfpi2 Tissue factor pathway inhibitor 2 
F09 Tgfb1 Transforming growth factor, beta 1 
F10 Tgfb2 Transforming growth factor, beta 2 
F11 Tgfb3 Transforming growth factor, beta 3 
F12 Timp1 Tissue inhibitor of metalloproteinase 1 
G01 Tmeff1 
Transmembrane protein with EGF-like and two follistatin-like 
domains 1 
G02 Tmem132a Transmembrane protein 132A 
G03 Tspan13 Tetraspanin 13 
G04 Twist1 Twist homolog 1 (Drosophila) 
G05 Vcan Versican 
G06 Vim Vimentin 
G07 Vps13a Vacuolar protein sorting 13A (yeast) 
G08 Wnt11 Wingless-related MMTV integration site 11 
G09 Wnt5a Wingless-related MMTV integration site 5A 
G10 Wnt5b Wingless-related MMTV integration site 5B 
G11 Zeb1 Zinc finger E-box binding homeobox 1 
G12 Zeb2 Zinc finger E-box binding homeobox 2 
H01 Gusb Glucuronidase, beta 
H02 Hprt Hypoxanthine guanine phosphoribosyl transferase 
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Position Symbol Description 
H03 Hsp90ab1 Heat shock protein 90 alpha (cytosolic), class B member 1 
H04 Gapdh Glyceraldehyde-3-phosphate dehydrogenase 
H05 Actb Actin, beta 
H06 MGDC Mouse Genomic DNA Contamination 
H07 RTC Reverse Transcription Control 
H08 RTC Reverse Transcription Control 
H09 RTC Reverse Transcription Control 
H10 PPC Positive PCR Control 
H11 PPC Positive PCR Control 
H12 PPC Positive PCR Control 
 
On complete analysis of three sets of the same sample using the online analysis programs 
provided by SAbiosciences (http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php) it 
was observed that there is a difference in regulation of certain genes in an isoform specific 




Figure 10 Comparison of fold change regulation of Twist1 expression levels in 01235 tumor 
cells with retention of Akt1 and Akt2 (controls), 0174 Akt1nulls and 0148 Akt2 nulls 
 
Twist1, a basic helix-loop-helix transcription factor with a major role in EMT, was not 
expressed in the cells missing Akt1 expression. (Ct values were obtained as raw data from the 
cycler and were processed to calculate ΔCt and ΔΔCt values in order to calculate gene 
expression. Ct value is defined as the number of cycles to cross the threshold value (exceeds 
background level) required for the fluorescent signal. The expression of Twist1 was retained in 
the cells having Akt1, in both control tumor cells and Akt2 null cells as shown in Figure 8. A 
similar pattern was found in the samples collected from the cells treated for EMT induction. 
Even though EMT was induced, which was confirmed by the change in cellular morphology as 





Snai2 (Slug) – Snai family player implicated in EMT, showed a similar pattern as Twist1. 
Loss of Akt1 reduced expression of Slug whereas Akt1 presence showed expression of Slug as 
demonstrated in Figure 9. 
 
Figure 11 Comparison of fold change regulation of Snai2 (Slug) expression levels in 01235 






Figure 12 Comparison of fold change regulation of Snai2 (Slug) and Twist1 expression levels in 
01235 tumor cells with retention of Akt1 and Akt2 (controls), 0174 Akt1nulls and 0148 Akt2 
nulls with and without induction of EMT 
 
These experiments were conducted in triplicates in order to be able to establish statistical 
significance in the form or P-values.  
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Table 8 P-values of Snai2 and Twist1 calculated from the samples in triplicates of the groups 
with and without EMT induced. 
 
 Snai2 Twist1 
0174 Akt1 null cells 0.040509 0.00792 
0148 Akt2 null cells  0.046475 0.013656 
 
Analysis of the Real time PCR data also indicated certain candidates, which were over 
expressed or de-regulated in the two different isoforms. 
 
Table 9 Fold regulation values determining over or under expression of genes in 0174 Akt1 null 









Bmp7 37.5942 Col3a1 -4.6443 
Col1a2 36.8143 Col5a2 -16.5536 
Dsc2 26.7498 Esr1 -19.8141 
Fgfbp1 5.4569 Fn1 -5.5858 
Il1rn 19.8512 Gng11 -12.3894 
Krt19 119.5645 Mmp3 -8.3825 
Ocln 23.842 Serpine1 -4.7551 
Snai3 7.5474 Snai2 -11.2836 
Sox10 4.1922 Tspan13 -88.8907 








Table 10 Fold regulation values determining over or under expression of genes in 0148 Akt2 null 









Bmp7 61.2847 Cald1 -4.0133 
Fgfbp1 15.7639 Cdh1 -7.8847 
Igfbp4 8.6613 Il1rn -8.7068 
Krt19 25.6732 Mtap1b -5.9455 
Pdgfrb 5.1161 Serpine1 -8.4769 
Rgs2 13.1008 Spp1 -80.9743 











Table 11 Fold regulation values determining over or under expression of genes in 0174 Akt1 null 









Col1a2 75.3493 Bmp1 -4.7141 
Dsc2 98.8236 Col3a1 -8.5963 
Il1rn 172.8414 Col5a2 -4.5213 
Jag1 4.804 Egfr -4.0675 
Krt19 4.6572 Esr1 -71.1346 
Mmp2 7.5597 Fn1 -7.0982 
Ocln 37.071 Foxc2 -4.0881 
Snai3 11.2095 Gsk3b -4.1318 
Sox10 4.1506 Igfbp4 -6.1823 
Spp1 480.9273 Mmp3 -11.6224 



















3.6 Validation at Protein levels 
 
 
Figure 13 Validation of real time findings using protein band determination. E-cadherin and β-
actin antibodies (Cell Signaling) were used and samples with and without induction of EMT 
were analyzed. 
 
The effect of reduced or no expression at RNA levels was seen on protein levels. E-
cadherin, whose expression is reduced by Twist1, was probed on the protein extracted from 
samples with and without EMT induction. It is observed that the 0174 Akt1 null tumor cells 
missing Akt1 and Twist1 show bands for E-cadherin. The 0148 Akt2 null tumor cells with Akt1 
expression and thus Twist1 expression do not show E-cadherin bands at protein levels. The 
appearance of E-cadherin bands in the cells with both Akt1 and Akt2 expression might be due to 




CHAPTER 4. DISCUSSION 
 
The Akt family of kinases is one of the most versatile players in cell biology affecting 
various cell processes namely proliferation, metabolism, survival, tumor development and EMT 
(Xue, Restuccia et al. 2012). This family of three important kinases Akt1, 2 and 3 has been 
widely studied for their implications in various cancers. With advancing literature updates it has 
been observed that Akt isoforms might have a tissue specific function in a matured tumor 
phenotype. There have been conflicting studies debating the role and mechanism of Akt1 
isoform in inhibition of cell motility and invasion in human breast cancer tissue. One study states 
that it is independent of ERK pathway, whereas another states proteosomal degradation of NFAT 
by Akt1 (Liu, Radisky et al. 2006). There has been evidence of Akt2 being transcriptionally up-
regulated by Twist1 in breast cancer tissue (Cheng, Chan et al. 2007). On the contrary, in lung 
cancer Akt1 is the predominant regulator of both proliferation and migration when compared to 
Akt2. These conflicting roles of Akt isoforms in different tissues affirm the need to delineate 
their roles in ovarian cancer. Using transgenic mice, in this study one type of tumor cells were 
derived from mice with genetic inactivation of Akt1 (0174 Akt1 knockout), other types with 
genetic inactivation of Akt2 (0148 Akt2 knockout) and a third type with retention of both Akt1 
and Akt2 (01235 control).  
While observing the cell migratory patterns using wound healing assays in the three 
different types of cells stated above, it was observed that Akt1 retention enhanced the migration 
of cells. Akt1 knockout cells had reduced migration rates. This result suggests a tissue specific 
reversal of roles of Akt1 when compared to human breast cancer tissue where Akt1 is said to 
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have anti-migratory role. Similar patterns were established with every repeat of the wound 
healing assay where the 0174 Akt1 knockout cells took much longer time to fill up the wound 
when compared to the cells with retention of Akt1 – 0148 Akt2 nulls and 01235 controls. Cell 
migration was tested using a different assay where the invasiveness of the cells was gauged using 
the BD BioCoat Matrigel Invasion chambers. Results obtained using this assay were similar to 
those of the wound healing assay. The wells containing Akt1 knockout cells demonstrated less 
invasive potential.  
The ability of tumor cells to migrate contributes to the metastasis of the tumor cells and is 
governed by a phenomenon called as epithelial-mesenchymal transition (EMT). EMT, a normal 
and necessary mechanism during embryonic development and embryogenesis, is undesirable and 
causes metastasis in cancers with advanced tumor stages. The signaling proteins involved in 
EMT remain more or less the same during both embryogenesis and metastasis. In order to obtain 
a better understanding about the role of Akt1 pertaining to cell migration, it was decided to look 
for unique differences in transcription factors involved in EMT. Real time PCR array 
(SAbiosciences, Qiagen) analysis involving 84 genes highly implicated in EMT was performed. 
There was a striking observation noted wherein the 0174 Akt1 knockout cells did not exhibit 
expression of Twist1, whereas cells with retention of Akt1 (0148 Akt2 knockouts and 01235 
controls) exhibited expression of Twist1 to a significant extent. Twist1 is a basic helix-loop-helix 
transcription factor, which plays a very important role in EMT by suppressing the expression of 
E-cadherin. E-cadherin holds the cells in epithelial phenotype and down regulation of E-cadherin 
is found in mesenchymal phenotype or the cells that have highly metastasized. By knocking out 
Akt1, Twist1 expression levels were not detectable and this might be one of the main reasons 
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why the Akt1 knockout cells took longer time to migrate and fill in the wound assay and also 
show less invasiveness. Similar patterns were found in Snai2 (Slug), another important regulator 
of EMT. There have been reports of the association of Akt2 with Twist1 in human breast cancer 
cells and further rationalizing of the role of Akt2 as an enhancer of cell migration in human 
breast cancer cells. With the RT profile analysis presented here there is an indication of a novel 
link, which could be used to establish that in murine ovarian tumor cells, Akt1 is associated with 
Twist1, thus rationalizing role of Akt1 as an enhancer of cell migration and invasion. 
 
Figure 14 A Schematic, indicating the series of events that may explain the observations in the 
cell model. Genetic inactivation of Akt1 leads to reduced expression of Twist1 and Slug, 
which in turn could not completely inhibit expression of E-cadherin. The reduced E-
cadherin levels may be due to Snail whose expression seems to be governed independent 
of the Akt isoform knockouts.Overall this phenomenon causes reduced motility in the 




The validity of this link was further tested by inducing EMT in the cells using a synergy 
between TGF β1 and EGF. There was a drastic change in morphology of the cells from epithelial 
to mesenchymal phenotype observed after 48 hours. The RT profile analysis showed a similar 
pattern of Twist1 missing in the cells without Akt1 and over expression of Twist1 in cells 
retaining Akt1.  
EMT in ovarian carcinoma has a reputation of being an exception to the norm. Although 
certain EMT markers in ovarian cancer show similar pattern of over-expression during EMT as 
in other types of cancer, there are certain basic players like E-cadherin and N-cadherin whose 
regulation patterns are not consistent with the data from other types of cancer during high 
metastasis. RT profiles suggest similar unconventionalities of the same markers in ovarian tumor 
cells used for my project. Typically E-cadherin should be repressed during induction of EMT. 
The profiles indicate change in RNA expression of E-cadherin but this finding could be more 
closely related to presence of Twist1 than to induction of EMT. The presence of Twist1 in cells 
with Akt1 exhibited low expression levels of E-cadherin as compared to cells missing Akt1 and 
Twist1 where E-cadherin is expressed in normal levels.  
There have been recent studies that suggest a cross talk between the PI3 kinase/Akt and 
TGF β signaling axes. The real time data indicate that the cells with loss of Akt1 exhibit reduced 
expression of TGF β2. The cells retaining Akt1 and loss of Akt2 exhibit increased TGF β2 and 
TGF β3 expression levels. This might indicate isoform specific channeling of the cross-talk 
between the two signaling pathways.   
The real time data is consistent to the speculation posed regarding the noncanonical 
nature of ovarian EMT. There is definitive link between Akt and EMT, where different isoforms 
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regulate protein effectors through specific associations. Since there are numerous players that 
might crosstalk to contribute to EMT, off-target regulation of one of the players does not block 
the process to a great significance aside from delaying the process. In spite of this robustness of 
EMT, clarifying the molecular mechanisms will increase the likelihood of improving therapeutic 
targeting.  
Validation at protein levels was used to show a consistent pattern affecting Twist1 loss 
and appearance of bands of E-cadherin. 0174 Akt1 knockouts, which lack Twist1 expression at 
RNA levels, showed strong bands corresponding to E-cadherin protein after western blot 
analysis. The 0148 Akt2 knockouts retaining Akt1 showed no bands for E-cadherin. Protein 
extracted from the cells with EMT induction also showed similar pattern. E-cadherin protein 
expression was diminished in the induced samples, which is consistent with induction of EMT. 
Thus, it is postulated that EMT induction should lead to complete loss of E-cadherin, which 
happens in cells retaining Akt1, but cells with the loss of Akt1 and subsequent loss of Twist1 do 
not show complete inhibition of E-cadherin reassuring the association or Akt1 and Twist1 at 
functional levels.  
This novel association between Akt1 and Twist1 in ovarian tumor cells needs to be 
further analyzed to understand the mechanistic link between the two. This could be achieved by 
silencing either of the two and in turn understanding the effect of one on the other. Although 
typically an exception to the norm, the data presented here suggest that EMT in ovarian cancer 
can be elucidated by understanding such novel links between the various hallmark cell signaling 
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